Scarica l'app Stockscreener
3.62
4.32%
0.15
Pre-mercato:
3.62
Precedente Chiudi:
$3.47
Aprire:
$3.4
Volume 24 ore:
623.44K
Relative Volume:
1.00
Capitalizzazione di mercato:
$781.29M
Reddito:
$596.48M
Utile/perdita netta:
$123.72M
Rapporto P/E:
6.601
EPS:
0.5484
Flusso di cassa netto:
$106.59M
1 W Prestazione:
+4.32%
1M Prestazione:
+13.48%
6M Prestazione:
+25.69%
1 anno Prestazione:
+24.40%
Intervallo 1D:
$3.40
$3.70
Intervallo di 1 settimana:
$3.26
$3.70
Portata 52W:
$2.37
$5.28
Curevac N V Stock (CVAC) Company Profile
Confronta CVAC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
3.62 | 781.29M | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Curevac N V Stock (CVAC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-04-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-06-08 | Iniziato | SVB Securities | Outperform |
| 2023-01-19 | Aggiornamento | UBS | Neutral → Buy |
| 2023-01-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Hold |
| 2021-06-17 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Underperform |
| 2021-04-26 | Iniziato | Guggenheim | Neutral |
| 2020-12-10 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2020-09-08 | Iniziato | BofA Securities | Buy |
| 2020-09-08 | Iniziato | Credit Suisse | Neutral |
| 2020-09-08 | Iniziato | Jefferies | Hold |
Mostra tutto
Curevac N V Borsa (CVAC) Ultime notizie
Analysts Offer Valuable Insight On CureVac N.V (CVAC) - Stocksregister
CureVac (NASDAQ:CVAC) Shares Gap Up – Should You Buy? - Defense World
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK - ACCESS Newswire
Geode Capital Management LLC Acquires 22,491 Shares of CureVac (NASDAQ:CVAC) - Defense World
UBS Group Lowers CureVac (NASDAQ:CVAC) Price Target to $12.00 - Defense World
CVAC (CureVac N.V) has impressive results - uspostnews.com
CureVac N.V. (NASDAQ:CVAC) Shares Fly 31% But Investors Aren't Buying For Growth - simplywall.st
Legal & General Group Plc Has $359,000 Holdings in CureVac (NASDAQ:CVAC) - Defense World
Understanding the Risks of Investing in CureVac N.V (CVAC) - knoxdaily.com
CureVac (CVAC) Target Price Reduced by UBS Analyst | CVAC Stock News - GuruFocus
UBS Trims Price Target on CureVac to $12 From $13, Maintains Buy Rating - marketscreener.com
CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet - ACCESS Newswire
CureVac N.V (CVAC) Stock: Navigating a Year of Stock Volatility - investchronicle.com
CureVac (NASDAQ:CVAC) Shares Gap Up – Here’s Why - Defense World
Can you still get a good price for CureVac N.V (CVAC) Shares at this point? - uspostnews.com
CureVac (CVAC) to Release Quarterly Earnings on Wednesday - Defense World
CureVac Among 3 Promising Penny Stocks To Watch - Yahoo Finance
CureVac (NASDAQ:CVAC) Trading Up 7.5% – Should You Buy? - Defense World
CureVac N.V. (NASDAQ:CVAC) Q4 2024 Earnings Call Transcript - Insider Monkey
CureVac N.V. Earnings Call: Financial Strength Amid Challenges - TipRanks
CureVac Stock Declines On Weaker-Than-Expected Q4 Revenue: Retail’s On Wait-And-Watch Mode - MSN
CureVac NV earnings beat by €0.06, revenue topped estimates - Investing.com South Africa
CureVac N.V. Reports Earnings Results for the Full Year Ended December 31, 2024 - marketscreener.com
CureVac: 2025 will be less costly - marketscreener.com
CureVac Announces Financial Results for the Fourth Quarter and F - GuruFocus
CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial Resilience - Yahoo Finance
CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial Resilience By GuruFocus - Investing.com Canada
CureVac NV (CVAC) Q4 2024 Earnings Call Highlights: Strategic Pa - GuruFocus
CureVac Reports Strong 2024 Financial Results and Strategic Progress - TipRanks
CureVac Reports 2024 Financial Results and Strategic Advances - TipRanks
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update - ACCESS Newswire
CureVac Q4 2024 Earnings Call Transcript - MarketBeat
Insights Ahead: CureVac's Quarterly Earnings - Benzinga
CureVac to initiate Phase 1 trial for its lung cancer therapy - MSN
FDA clears CureVac’s IND application for Phase I lung cancer trial - MSN
FDA clears Curevac’s IND for CVHNLC - BioWorld MedTech
EQS-News: CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 - sharewise.com
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 - ACCESS Newswire
CureVac Financial Results: Key mRNA Biotech Player to Reveal 2024 Performance - Stock Titan
CureVac’s lung cancer therapy clears FDA hurdle - Investing.com Australia
CureVac’s lung cancer therapy clears FDA hurdle By Investing.com - Investing.com South Africa
CureVac's Early-stage Trial of Lung Cancer Drug Gets US FDA Clearance - MarketScreener
CureVac to initiate Phase 1 trial for its lung cancer therapy (CVAC:NASDAQ) - Seeking Alpha
CureVac Receives FDA Clearance to Initiate Phase 1 Trial of Lung Cancer Therapy - MarketScreener
EQS-News: CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer - sharewise.com
Curevac N V Azioni (CVAC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):